/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Acquisition of Pre-Merger Oruka On August 29, 2024 (the Merger Closing ), we completed our acquisition (the Merger ) of Oruka Therapeutics, Inc. ( Pre-Merger Oruka ) pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the Merger Agreement ). Following the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger …
$92.20
$3.73 (-3.89%)
EOD Sep 15, 2026
Negative free cash flow of -$88M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$133M
Op. Margin
—
ROIC
-19.08%
Cash Flow & Balance Sheet
FCF (TTM)
-$101M
Op. Cash Flow (TTM)
-$101M
Net Debt
-$871M
Net Cash Position
Cash & Equiv.
$874M
Continue Research
SourceComputed from the 10-Q filed 10 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 11 Aug 2026. How this is calculated.
Price from market data, last close as of 15 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Oruka Therapeutics (ORKA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Oruka Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Oruka Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -19.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ORKA's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.